GANX
Companies
NASDAQ
Gain Therapeutics Inc.
Health Care
$1.79
-$0.37 (-17.13%)
Price Chart
Overview
About GANX
gain therapeutics is a preclinical stage biotech company specializing in the discovery of new drugs for orphan diseases. the company targets inborn errors of metabolism; a group of rare diseases of genetic origin with a high unmet medical need. gain therapeutics is also working on a new class of compounds: non-competitive pharmacological chaperones, identified through its innovative proprietary platform – see-tx. the gain therapeutics team is made up of a group of drug discovery and development experts with several decades of experience in biotech and pharma.
Market Cap
$39.7M
Volume
437.0K
Avg. Volume
533.1K
P/E Ratio
-2.1398876
Dividend Yield
0.00%
Employees
29.0
Company Information
Risk & Correlation Analysis
Market Correlation
0.89
Moderate Correlation
Volatility
High (1.00)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
High Sensitivity
GDP Growth
High Sensitivity
Liquidity
Medium Sensitivity
Commodity Prices
Medium Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, GANX shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$39.7M
Volume437.0K
P/E Ratio-2.14
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 14, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025